Synthetic vectors for therapeutic nucleic acid delivery are currently competing significantly
with their viral counter parts due to their reduced immunogenicity, large payload capacity …

The promise of therapeutic nucleic acids has long been tempered by difficulty in overcoming
biological barriers to their delivery. The past two decades have seen the development of …

The successful development of nonviral delivery systems for nucleic acids has been
reported extensively over the past number of years. Among them, lipid-based nanoparticles …

Since their inception in the 1980s, oligonucleotide-based (ON-based) therapeutics have
been recognized as powerful tools that can treat a broad spectrum of diseases. The …

Although activity has been reported in vivo, free nucleic acid-based drugs are rapidly
degraded and cleared following systemic administration. To address these challenges and …

The field of gene therapy has experienced an insurgence of attention for its widespread
ability to regulate gene expression by targeting genomic DNA, messenger RNA, microRNA …

The last few years have witnessed a great advance in the development of nonviral systems
for in vivo targeted delivery of nucleic acids. Lipid nanoparticles (LNPs) are the most …

Ribonucleic acid (RNA) has emerged as one of the most promising therapeutic payloads in
the field of gene therapy. There are many unique types of RNA that allow for a range of …

Lipid nanoparticles (LNPs) are the most advanced nonviral modality for nucleic acid (NA)
delivery, and have recently gained enormous attention in the fields of RNA therapeutics and …

Gene therapy for many diseases is rapidly becoming a reality, as demonstrated by the
recent approval of various nucleic acid-based therapeutics. Non-viral systems such as lipid …